Stockscreener 앱 받기
1.79
6.55%
0.11
전일 마감가:
$1.68
열려 있는:
$1.69
하루 거래량:
86,334
Relative Volume:
0.30
시가총액:
$9.85M
수익:
$468.00K
순이익/손실:
$-10.34M
주가수익비율:
-0.2539
EPS:
-7.05
순현금흐름:
$-8.94M
1주 성능:
-15.96%
1개월 성능:
-21.83%
6개월 성능:
-24.31%
1년 성능:
-34.19%
1일 변동 폭
$1.69
$1.805
1주일 범위
$1.65
$1.96
52주 변동 폭
$1.625
$4.66
Biocardia Inc Stock (BCDA) Company Profile
명칭
Biocardia Inc
전화
650-226-0123
주소
320 SOQUEL WAY, SUNNYVALE, CA
BCDA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| 0.41 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
0.70 | 979.09M | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.28 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
2.65 | 111.10M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.168 | 327.43M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DAVEW
Dave Inc
|
1.30 | 0 | 0 | 0 | 0 | 0.00 |
Biocardia Inc Stock (BCDA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-04-16 | 다운그레이드 | Dawson James | Buy → Neutral |
Biocardia Inc 주식(BCDA)의 최신 뉴스
Full technical analysis of BioCardia Inc. stockWeekly Market Direction and Sector Summary - Newser
Should you wait for a breakout in BioCardia Inc.Stock Trading Session Highlights and Summary - Newser
What candlestick patterns are forming on BioCardia Inc.Day Trading Setup Forecast with Trend Model - Newser
Is BioCardia Inc. still worth holding after the dipPrice Movement and Market Sentiment Analysis - Newser
Is BioCardia Inc. forming a reversal patternInstitutional Holding Behavior Pattern Analysis - Newser
Biocardia BCDA 2025Q2 Earnings Preview Upside Ahead on Strategic Product Developments - AInvest
Can momentum traders help lift BioCardia Inc.Alpha Generation Strategy with Low Volatility - Newser
How BioCardia Inc. stock performs during market volatilityFree Investment Plan With Growth Optimization - Newser
BioCardia to Host Q2 2025 Earnings Call on August 11 - AInvest
Real time social sentiment graph for BioCardia Inc.Free Alpha Driven Watchlist With Alerts - Newser
Can BioCardia Inc. recover in the next quarterAnnual Market Behavior and Sector Summary - Newser
BioCardia to Host Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025 - GlobeNewswire
Has BioCardia Inc. formed a bullish divergenceFree Weekly Stock Watch With Growth Focus - Newser
Earnings Preview: BioCardia to Report Financial Results Post-market on August 11 - 富途牛牛
BioCardia Announces Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025 - AInvest
Cellular Therapeutics Pioneer BioCardia Announces Q2 2025 Earnings and Pipeline Update - Stock Titan
Is BioCardia Inc. meeting your algorithmic filter criteriaCapital Growth Summary Over Five Years - Newser
What recovery options are there for BioCardia Inc.Weekly High Conviction Trade Setup Analysis - Newser
Will breakout in BioCardia Inc. lead to full recoveryVolatility Analysis and Entry Risk Mapping - Newser
BioCardia Reveals Plans to Request Meeting With FDA Regarding CardiAMP Heart Failure Cell Therapy - CGTLive®
BioCardia Seeks FDA Approval for CardiAMP and Helix Transendocardial Delivery Catheter - AInvest
New Strong Sell Stocks for August 5th - The Globe and Mail
Biocardia Stock Plunges 12.76% Amid Market Volatility - AInvest
Biocardia, Inc. shares fall 12.76% premarket after providing update on regulatory approvals. - AInvest
Biocardia, Inc. shares fall 5.61% premarket after providing update on regulatory activities. - AInvest
What makes BioCardia Inc. stock price move sharplyLong-Term Safety Investment Analysis Report - Newser
BioCardia Faces Market Slump as Resale Registration Trigger Shares Drop - StocksToTrade
Biocardia, Inc. shares fall 14.51% intraday after providing update on regulatory activities. - AInvest
What institutional flow reveals about BioCardia Inc.Technical Screener for High Growth Stocks - Newser
BioCardia Updates Regulatory Timeline for Helix System - TipRanks
BioCardia's 2025 Regulatory Momentum: A Dual-Track Strategy for U.S. and Japanese Market Access - AInvest
BioCardia Provides Update on Timing of Regulatory Activities Seeking FDA Approval and Japan PMDA Approval for CardiAMP® Cell Therapy for Heart Failure and Helix™ Transendocardial Delivery Catheter | B - GuruFocus
BioCardia to Seek FDA Approval for CardiAMP Cell Therapy in Q3 2025. - AInvest
BioCardia Provides Update on Timing of Regulatory Activities Seeking FDA Approval and Japan PMDA Approval for CardiAMP® Cell Therapy for Heart Failure and Helix™ Transendocardial Delivery Catheter - GlobeNewswire
BioCardia's Revolutionary Heart Failure Treatment Advances Toward FDA Approval: Key Timeline Released - Stock Titan
Chart based analysis of BioCardia Inc. trendsFree Fast Gaining Stock Screener Report - Newser
What is the dividend policy of BioCardia Inc. stockRapid capital growth - Jammu Links News
What drives BioCardia Inc. stock priceGet daily expert analysis on top stocks - Jammu Links News
How does BioCardia Inc. compare to its industry peersGet real-time alerts on top stocks - Jammu Links News
Why is BioCardia Inc. stock attracting strong analyst attentionCapitalize on momentum-driven investment opportunities - Jammu Links News
Chart overlay techniques for tracking BioCardia Inc.Market Sentiment Tracker with Smart Alerts - newser.com
What institutional investors are buying BioCardia Inc. stockFree Stock Market Forecast Reports - Jammu Links News
What are the latest earnings results for BioCardia Inc.Build wealth faster with consistent investment plans - Jammu Links News
Biocardia Inc (BCDA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):